Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.50 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.39 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12914745 | 0.98 | CYP3A4 (0.63) | CYP3A4TSHRLPAR3LPAR2LPAR1 | |
| SCHEMBL2520487 | 0.94 | CYP3A4 (0.69) | CYP3A4TSHRLPAR3LPAR2LPAR1 | |
| SCHEMBL11515777 | 0.94 | CYP3A4 (0.69) | CYP3A4TSHRLPAR3LPAR2LPAR1 | |
| SCHEMBL12914744 | 0.91 | CYP3A4 (0.61) | CYP3A4TSHRLPAR3LPAR2LPAR1 | |
| Ammonia Solution, Strong SCHEMBL5519376 | 0.91 | CYP3A4 (0.61) | CYP3A4TSHRLPAR3LPAR2LPAR1 | |
| SCHEMBL26758426 | 0.90 | TSHR (0.57) | CYP3A4TSHRLPAR3LPAR2LPAR1 | |
| SCHEMBL19512084 | 0.90 | LPAR3 (0.60) | CYP3A4TSHRLPAR3LPAR2LPAR1 | |
| SCHEMBL26420468 | 0.90 | CYP3A4 (0.55) | CYP3A4TSHRLPAR3LPAR2LPAR1 | |
| SCHEMBL27743684 | 0.90 | TSHR (0.57) | CYP3A4TSHRLPAR3LPAR2LPAR1 | |
| SCHEMBL17333150 | 0.89 | CYP3A4 (0.57) | CYP3A4TSHRLPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245717-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | LAKEWOOD AMEDEX INC (US) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245717-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | EIF2AK2, MAVS, TYMP | CYP3A4 962/4885TSHR 4713/4885LPAR3 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.